These findings are in agreement with the in vitro findings, suggesting that 3BDO suppresses tumor growth by inhibiting survivin-mediated EMT and stemness in glioblastoma xenograft models, thereby highlighting its potential as a therapeutic GBM candidate. This evidence concerns the gene BIRC5 and glioblastoma.